Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.

@article{Falchook2015AuroraKI,
  title={Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress.},
  author={Gerald Steven Falchook and Christel C Bastida and Razelle Kurzrock},
  journal={Seminars in oncology},
  year={2015},
  volume={42 6},
  pages={832-48}
}
The Aurora kinase family of kinases (Aurora A, B, and C) are involved in multiple mitotic events, and aberrant expression of these kinases is associated with tumorigenesis. Aurora A and Aurora B are validated anticancer targets, and the development of Aurora kinase inhibitors has progressed from preclinical to clinical studies. A variety of Aurora A, B and pan-Aurora kinase inhibitors have entered the clinic. The main side effects include febrile neutropenia, stomatitis, gastrointestinal… CONTINUE READING